Osteoporosis and venous thromboembolism: a retrospective cohort study in the UK general practice research database
Osteoporosis and venous thromboembolism: a retrospective cohort study in the UK general practice research database
Summary:
In a retrospective cohort study using the General Practice Research Database (GPRD), there was a greater association of venous thromboembolism (VTE) in osteoporotic than in non-osteoporotic female patients. No greater association was shown in treated patients with strontium ranelate or alendronate compared to untreated osteoporotic female patients.
Introduction
We explored the risk of VTE in usual practice in osteoporotic and non-osteoporotic women with and without anti-osteoporotic treatment.
Methods:
A retrospective study was conducted using the GPRD in the UK. The cohorts consisted of untreated osteoporotic women (N?=?11,546), osteoporotic women treated with alendronate (N?=?20,084), or strontium ranelate (N?=?2,408), and a sample of non-osteoporotic women (N?=?115,009). Cohorts were compared using a Cox proportional hazards regression model.
Results:
There was a significantly increased relative risk for VTE in untreated osteoporotic women versus non-osteoporotic women (annual incidence 5.6 and 3.2 per 1,000 patient–years, respectively; relative risk 1.75 [95% confidence interval (CI), 1.09–1.84]). Results were confirmed using adjusted models. The annual incidences of VTE in osteoporotic patients treated with strontium ranelate and alendronate were 7.0 and 7.2 per 1,000 patient–years, respectively, with no significant difference between untreated and treated patients whatever the treatment. Adjusted hazard ratios for treated versus untreated osteoporotic women were 1.09 (95% CI, 0.60–2.01) for strontium ranelate and 0.92 (95% CI, 0.63–1.33) for alendronate.
Conclusion:
This study shows a greater association of VTE in osteoporotic compared to non-osteoporotic patients, but does not show any greater association in treated patients with strontium ranelate or alendronate compared to untreated osteoporotic patients.
alendronate sodium, GPRD, osteoporosis, risk factors, strontium ranelate, venous thromboembolism
1181-1187
Breart, G.
6f2520fc-06ca-4edd-9701-4567f565bfd2
Cooper, C.
e05f5612-b493-4273-9b71-9e0ce32bdad6
Meyer, O.
4a681acd-4f32-4057-a28f-247fffae287c
Speirs, C.
f0f98fb1-19ed-4d8d-a4ce-485eb9958b32
Deltour, N.
260401d7-9bab-49d1-bfac-198266c1bb2a
Reginster, J. Y.
7de6c80d-0c90-4c29-a071-a7908edc631b
July 2010
Breart, G.
6f2520fc-06ca-4edd-9701-4567f565bfd2
Cooper, C.
e05f5612-b493-4273-9b71-9e0ce32bdad6
Meyer, O.
4a681acd-4f32-4057-a28f-247fffae287c
Speirs, C.
f0f98fb1-19ed-4d8d-a4ce-485eb9958b32
Deltour, N.
260401d7-9bab-49d1-bfac-198266c1bb2a
Reginster, J. Y.
7de6c80d-0c90-4c29-a071-a7908edc631b
Breart, G., Cooper, C., Meyer, O., Speirs, C., Deltour, N. and Reginster, J. Y.
(2010)
Osteoporosis and venous thromboembolism: a retrospective cohort study in the UK general practice research database.
Osteoporosis International, 27 (7), .
(doi:10.1007/s00198-009-1050-7).
Abstract
Summary:
In a retrospective cohort study using the General Practice Research Database (GPRD), there was a greater association of venous thromboembolism (VTE) in osteoporotic than in non-osteoporotic female patients. No greater association was shown in treated patients with strontium ranelate or alendronate compared to untreated osteoporotic female patients.
Introduction
We explored the risk of VTE in usual practice in osteoporotic and non-osteoporotic women with and without anti-osteoporotic treatment.
Methods:
A retrospective study was conducted using the GPRD in the UK. The cohorts consisted of untreated osteoporotic women (N?=?11,546), osteoporotic women treated with alendronate (N?=?20,084), or strontium ranelate (N?=?2,408), and a sample of non-osteoporotic women (N?=?115,009). Cohorts were compared using a Cox proportional hazards regression model.
Results:
There was a significantly increased relative risk for VTE in untreated osteoporotic women versus non-osteoporotic women (annual incidence 5.6 and 3.2 per 1,000 patient–years, respectively; relative risk 1.75 [95% confidence interval (CI), 1.09–1.84]). Results were confirmed using adjusted models. The annual incidences of VTE in osteoporotic patients treated with strontium ranelate and alendronate were 7.0 and 7.2 per 1,000 patient–years, respectively, with no significant difference between untreated and treated patients whatever the treatment. Adjusted hazard ratios for treated versus untreated osteoporotic women were 1.09 (95% CI, 0.60–2.01) for strontium ranelate and 0.92 (95% CI, 0.63–1.33) for alendronate.
Conclusion:
This study shows a greater association of VTE in osteoporotic compared to non-osteoporotic patients, but does not show any greater association in treated patients with strontium ranelate or alendronate compared to untreated osteoporotic patients.
This record has no associated files available for download.
More information
Published date: July 2010
Keywords:
alendronate sodium, GPRD, osteoporosis, risk factors, strontium ranelate, venous thromboembolism
Identifiers
Local EPrints ID: 152077
URI: http://eprints.soton.ac.uk/id/eprint/152077
ISSN: 0937-941X
PURE UUID: 158ec7de-48d8-4d82-80e6-051c3be8d820
Catalogue record
Date deposited: 13 May 2010 13:44
Last modified: 18 Mar 2024 02:44
Export record
Altmetrics
Contributors
Author:
G. Breart
Author:
O. Meyer
Author:
C. Speirs
Author:
N. Deltour
Author:
J. Y. Reginster
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics